In vitro only: human rhabdomyosarcoma cells and normal primary myoblasts
“The pharmacological activity of casimersen was tested in vitro using human rhabdomyosarcoma cells and normal primary myoblasts, as there are no relevant animal models due to the species- and mutation-specific nature of PMO ASOs.”
✓ VerifiedFDA pharmacology/toxicology review, p. 3Source ↗
Why that model
No relevant animal models due to species- and mutation-specific nature of PMO ASOs
“The pharmacological activity of casimersen was tested in vitro using human rhabdomyosarcoma cells and normal primary myoblasts, as there are no relevant animal models due to the species- and mutation-specific nature of PMO ASOs.”
✓ VerifiedFDA pharmacology/toxicology review, p. 3Source ↗
Reviewer's view of the efficacy data
Class proof of concept accepted from prior mdx mouse studies with murine surrogate AVI-4225 (IND 77429)
“Proof of concept studies for the exon skipping activity of the oligonucleotide drugs such as SRP-4045 was demonstrated in studies originally submitted and reviewed under IND 77429 in which the murine surrogate PMO, AVI-4225, was used in the mdx mouse”
✓ VerifiedFDA pharmacology/toxicology review, p. 18Source ↗